JAMA Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
《美国医学会肿瘤学杂志》是一本国际同行评审期刊，也是肿瘤学领域科学家、临床医生和实习生的权威期刊。JAMA Oncology是JAMA网络的成员，JAMA网络是一个由同行评审、普通医学和专业出版物组成的联盟。
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.4224
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.4051
Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.4280
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.1022
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.5904
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.0402
Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.2311
Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2019.0349
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.6012
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.3692
Association Between Aspirin Use and Biliary Tract Cancer Survival
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2019.4328
Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2018.6196
Body Composition and Cardiovascular Events in Patients With Colorectal Cancer: A Population-Based Retrospective Cohort Study.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.0695
Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.4107
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.5140
Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.2095
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.0836
The Role of Disease Label in Patient Perceptions and Treatment Decisions in the Setting of Low-Risk Malignant Neoplasms.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.0054
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.3869
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.6607
Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.4587
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.4114
Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.5911
Long-term Somatic Disease Risk in Adult Danish Cancer Survivors
来源期刊：JAMA OncologyDOI：10.1001/jamaoncol.2018.7192
Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.1760
Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.1973
Population-Based Quality Indicators for End-of-Life Cancer Care: A Systematic Review.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.3388
Global Variation in Opioid Use in Prostate Cancer Trials.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.2971
Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.4648
Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer.
来源期刊：JAMA oncologyDOI：10.1001/jamaoncol.2019.5102
